Cardiovascular risk estimation in non alcoholic fatty liver disease

##plugins.themes.academic_pro.article.sidebar##

Published Sep 20, 2017
Download
pdf
Vol. 94 No. 12 (2016): Issue Dec 2016

##plugins.themes.academic_pro.article.main##

Hayfa Romdhane
Service de Gastro-entérologie A. Hôpital la Rabta. Tunis
Myriam Cheikh
Rym Ennaifer
Service de Gastro-entérologie Hôpital H. Thameur Tunis
Yasmine Mahmoud
Wassila Bougassas
Houda Ben Nejma
Najet Bel Hadj

Abstract

Background : Nonalcoholic fatty liver disease is rising to the growing epidemic of metabolic syndrome. Recent data suggest that this liver disease may represent a real marker of cardiovascular risk. The aim of our study was to calculate cardiovascular risk and to estimate the frequency of subclinical coronary artery disease by conducting an exercise testing.

Methods : This is a prospective study conducted over a period of one year including all patients followed for non alcoholic fatty liver disease. We realized in all patients an exercise testing and we calculated the ACC / AHA score that estimates the risk of developing atherosclerotic cardiovascular disease. This risk is considered very high if the score> 7.5.

Results : We included 103 patients. The mean age was 52 years. The sex ratio (M/F) was 0.3. Diabetes, dyslipidemia and hypertension were present respectively in 45.6%, 48.5% and 38.8% of cases. Obesity was noted in 69.9% of our patients. Metabolic syndrome was found in 78.6% of patients. The ACC / AHA average score was 8.03 ± 9 and a score> 7.5 was noted in 35.9% of cases. The exercise testing was positive in 12 patients (11.65%). Of these, 11 underwent coronary angiography which was normal in 10 cases and showed a coronary artery infiltration without significant stenosis in only one case, and 2 patients underwent coro-scanner which was without significant anomalies. In univariate analysis, the presence of metabolic syndrome (p = 0.05), waist circumference ≥ 94 cm in men and ≥ 80 cm in women (p = 0.019), diabetes (p = 0.03) were associated with a high risk of developing cardiovascular events. In multivariate analysis, the only independent variable associated with a positive exercise testing was diabetes (OR 4.5, p = 0.03).

Conclusion : During non alcoholic fatty liver disease, there is an increased cardiovascular risk. It would be necessary to consider this excess risk in the surveillance of patients followed for non alcoholic liver disease to early detection of any cardiovascular disease.

Keywords:

Fatty liver disease, cardiovascular risk, metabolic syndrome, exercise testing

##plugins.themes.academic_pro.article.details##

References

  1. Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol. 2013;167:1109-17.
  2. Castera L. Noninvasive tools for the diagnosis of steatosis and fibrosis in patients with NAFLD. Gastroentérologie Clinique et Biologique. 2009;33:405-12.
  3. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, ShawJ. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb. 2005;12:295-300.
  4. Hudson S, Bhatia L, Mc Cormick KG, Bateman A, Nash K, Curzen NP, et al. Non-alcoholic fatty liver disease severity is related to increased cardiovascular risk independently of hyperglycaemia and obesity. Diabetologia 2011;54:S110.
  5. Domanski JP, Park SJ, Harrison SA. Cardiovascular disease and nonalcoholic fatty liver disease: does histologic severity matter? J Clin Gastroenterol. 2012;46:427-30.
  6. Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol. 2005;11:4838-42.
  7. Lopez-Suarez A, Guerrero JM, Elvira-Gonzalez J, Beltran-Robles M, Canas-Hormigo F, Bascunana-Quirell A. Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and non hypertensive individuals from the general population with normal levels of alanine aminotransferase. Eur J Gastroenterol Hepatol. 2011;23:1011-7.
  8. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212-8.
  9. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005;54:3541-6.
  10. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:521-33.
  11. Tolman KG, Fonseca V, Tan MH, Dalpiaz A. Narrative review: Hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med. 2004;141:946-56.
  12. Jousilahti P, Rastenyte D, Tuomilehto J. Serum gamma-glutamyl transferase, self-reported alcohol drinking, and the risk of stroke. Stroke. 2000;31:1851-5.
  13. Kozakova M, Palombo C, Eng MP, Dekker J, Flyvbjerg A, Mitrakou A, et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology. 2012;55:1406-15
  14. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis. 2007;191:391-6.
  15. Wang CC, Lin SK, Tseng YF, Hsu CS, Tseng TC, Lin HH, et al. Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2009;24:1411-6.